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ABSTRACT
This report describes the development of hemolysis in eighteen glucose-6-phosphate dehydroge-
nase defi cient patients treated for Plasmodium vivax malaria with chloroquine and primaquine. The 
most frequent fi ndings accompanying hemolysis were fever and leukocytosis, in addition to anemia 
requiring red blood cell transfusion, and development of acute renal failure. Hemolysis in patients 
using primaquine is not infrequent and contributes to the morbidity of infection caused by Plasmo-
dium vivax.
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INTRODUCTION
In 2007, Brazil reported 457,659 cases of ma-
laria, mostly in the Brazilian Amazon, with 
85% caused by P. vivax infection.1 Because of 
its ability to promote relapses from hypnozoites 
in the liver, the radical treatment of P. vivax in-
fection requires the use of chloroquine (blood-
stage schizonticidal drug) and primaquine, 
an 8-aminoquinoline that remains the only 
licensed tissue-stage schizonticidal drug.2 The 
recommended dosage of chloroquine is 10 mg/
kg/day in the fi rst day followed by 7.5 mg/kg/
day in the second and third days; the dosage 
of primaquine is 0.5 mg/kg/day for 7 days, ac-
cording to the Brazilian Antimalarial Therapy 
Guidelines.3 Despite of a slightly lower effi cacy 
compared to the 14-day regimen (0.25 mg/kg/
day) recommended by the World Health Or-
ganization, the 7-day regimen (0.5 mg/kg/day) 
adopted by the Brazilian Ministry of Health 
leads to better compliance.4 Primaquine how-
ever, has hemolytic anemia a notable adverse 
effect in patients with glucose-6-phosphate de-
hydrogenase (G6PD) defi ciency.5 This is an X-
linked recessive enzymatic defect in the hexose 
mono-phosphate shunt, which prevents cellu-
lar damage from oxidative stress.6 Therefore, 
the majority of affected cases are males. Ho-
mozygous symptomatic women are rare. The 
common African variant G6PD A- is usually a 
mild/moderate defi ciency (10−15% of normal 
activity in hemizygous males). In contrast, the 
G6PD Mediterranean variant is more severe 
(< 1% of normal activity).7
In Manaus (Western Brazilian Amazon), 
an association between G6PD defi ciency and 
methemoglobinemia without signifi cant se-
verity was detected.8 In spite of the widespread 
use of primaquine in tropical areas highly en-
demic for P. vivax species, the clinical aspects 
of hemolysis triggered by its use are poorly 
described in the literature, sometimes leading 
to inappropriate management of these cases 
in the health system.
PATIENTS AND METHODS
We report a series of 18 male patients with 
P. vivax infection referred to the Tropical Med-
icine Foundation of Amazonas, a tertiary-care 
unit for infectious diseases in Manaus, Brazil, 
from August 2006 to August 2007. All of these 
patients had been treated by primaquine and 
developed hemolysis (indirect bilirubin > 
1.0 mg/dL). They were all ultimately diag-
nosed with G6PD-defi ciency, by the qualita-
tive Brewer´s test.9 This test was repeated after 
120 days in all patients with an initial negative 
G6PD defi ciency test because of the transitory 
G6PD increase related to reticulocytosis dur-
ing an acute hemolytic crisis.
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Table 1. Clinical and laboratory characteristics of 18 patients with P. vivax infection with primaquine-induced 
hemolysis
 Patient Age Type of Fever Peripheral Time on Leukocytes Hgb Creatinine Indirect Time of Need for 
 number (years) malaria (admis- parasitemia primaquine /mm3 (g/dL) (mg/dL) bilirubin hospita- RBC
    sion) (admission) (days)    (mg/dL) lization trans-
           (days) fusion
 1 19 P.v. + - 3 13,600 10.3 N/A 3.04 7 -
 2 10 P.v. - - 6 16,400 6.1 0.9 1.40 3 -
 3 17 P.f. + P.v. + - 1 15,300 6.8 1.2 7.47 11 +
 4 12 P.v. + - 5 9,800 8.0 0.5 4.98 3 -
 5 21 P.v. + - 3 17,000 10.0 0.9 3.85 3 +
 6 14 P.v. - - 5 24,700 9.0 5.9 1.22 9 +
 7 32 P.v. - + 2 6,600 12.7 1.0 8.60 2 -
 8 39 P.v. + - 2 5,800 10.9 1.8 5.68 4 -
 9 12 P.v. + - 5 12,500 6.1 0.5 3.62 4 +
 10 23 P.v. - - 4 12,700 5.9 2.2 4.56 5 +
 11 21 P.v. - - 5 11,400 9.1 1.3 3.54 8 +
 12 15 P.v. - - 5 17,200 6.3 2.1 5.03 7 +
 13 17 P.v. + - 3 12,800 7.9 0.7 6.44 2 +
 14 11 P.v. + - 4 26,400 7.0 0.6 1.83 5 -
 15 8 P.v. + - 5 10,400 5.2 N/A 1.43 3 +
 16 12 P.v. + - 5 12,100 6.4 N/A 3.92 2 +
 17 31 P.f. + P.v. + + 5 15,300 9.9 0.9 4.77 3 +
 18 19 P.v. + - 4 6,400 8.4 0.9 3.10 3 +
P.v., Plasmodium vivax; P.f., Plasmodium falciparum; Hgb, hemoglobin; RBC, red blood cells; N/A, non-available.
 
RESULTS 
The major clinical symptoms of these patients were: jaundice 
(18/18), pallor (17/18), dark urine (14/18), fever (12/18), vomit-
ing (10/18), dehydration (6/18), cyanosis (3/18), and low urinary 
output (1/18). Table 1 details some clinical and laboratory char-
acteristics. No patient was treated with antibiotics, despite the 
presence of fever and leukocytosis.
DISCUSSION
In a smaller patient sample, Silva et al. detected similar 
clinical manifestations among G6PD-defi cient patients 
using primaquine in the State of Pará (Eastern Brazilian 
Amazon).10 Most of our patients were already negative for 
Plasmodium parasites when admitted to the hospital, re-
ﬂ ecting an adequate response to chloroquine. The onset of 
symptoms related to hemolysis emerged 1-6 days after start-
ing primaquine, supporting the need for routine follow-up 
of male patients during this interval, since patients are not 
tested routinely for G6PD defi ciency before the prescription 
of antimalarials in Brazil. Eleven out of the 18 patients still 
complained of fever, despite negative peripheral parasitemia, 
and 12 had leukocytosis (leukocyte count > 12,000/mm3), 
which could be attributed to the hemolytic crisis itself. Like-
wise, in two American soldiers returning from Iraq who 
developed hemolytic anemia and leukocytosis while receiv-
ing primaquine prophylaxis for malaria, routine wide spec-
trum antimicrobials were not started.11 The most clinically 
relevant complication in these patients was anemia, which 
required red blood cells transfusion in 12 of the 18 patients, 
leading to a substantial increase in hospitalization costs. 
Three patients who developed acute renal failure resolved 
favorably and did not require hemodialysis. One patient 
developed severe acute renal failure that required hemodi-
alysis. This patient was not included in the analysis because 
he was lost to follow-up and the diagnosis of G6PD defi -
ciency could not be reliably ascertained (data not shown). 
Therefore, acute renal failure in the tropics should raise the 
consideration of primaquine-triggered hemolysis in G6PD-
defi cient individuals.12 Rhabdomyolysis as the cause of acute 
renal failure was not investigated in our patients because 
none referred signifi cant myalgia.
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A better characterization of hemolysis could have been 
achieved with the reticulocyte percentage and haptoglobin 
level estimates. However, these laboratorial tests are not al-
ways available in most of the malaria endemic areas.
Further studies are needed to determine the magnitude 
of this problem in the primary care units in malaria endemic 
areas, especially in Latin America where P. vivax predomi-
nates and G6PD defi ciency is estimated to be around 3%.13 
A better understanding of this hematological complication 
will support the development of guidelines reinforcing the 
correct clinical management of hemolysis developing in pa-
tients during treatment for malaria.
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